MediGene AG (MDG1) Given a €12.00 Price Target at Oddo Securities

MediGene AG (ETR:MDG1) has been given a €12.00 ($14.12) target price by Oddo Securities in a report released on Tuesday, August 8th. The firm currently has a “buy” rating on the stock.

Other equities analysts have also issued research reports about the company. Baader Bank set a €19.00 ($22.35) target price on MediGene AG and gave the company a “buy” rating in a report on Saturday, May 20th. Independent Research GmbH set a €12.00 ($14.12) price objective on MediGene AG and gave the stock a “neutral” rating in a report on Monday, May 29th.

Shares of MediGene AG (ETR:MDG1) traded up 1.33% on Tuesday, reaching €9.12. The company had a trading volume of 15,959 shares. The firm’s market capitalization is €201.72 million. MediGene AG has a 12 month low of €6.65 and a 12 month high of €15.19. The firm’s 50 day moving average is €10.37 and its 200 day moving average is €11.48.

COPYRIGHT VIOLATION NOTICE: This report was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The original version of this report can be read at

About MediGene AG

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors.

What are top analysts saying about MediGene AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MediGene AG and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit